396: A new trick for old science, and biotech VCs' scrambled playbook
Why is old exon science getting new traction? What’s unsettling biotech VCs? And who will be the next CEO of PhRMA? Adam is out, so Elaine and Allison dive into the latest news, including how China and artificial intelligence are straining biotech VC firms, in addition to more M&A. They also discuss how a cancelled Food and Drug Administration meeting led to a biotech’s demise. Plus, there’s new hope for an old theory on treating Duchenne muscular dystrophy. STAT reporter Jason Mast details the clinical testing underway.
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from The Readout Loud
399: Hair-raising trial results, and Servier’s M&A wishlist
398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts
397: A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment
395: Biotech investors' plea to Trump, and a busy M&A week
Get summaries like this every morning.
Free AI-powered recaps of The Readout Loud and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.